A common cancer treatment that might be doing too much
For decades, locally advanced rectal cancer has been treated with chemotherapy combined with radiation before surgery. The combination shrinks tumors and reduces the chance of cancer coming back at the surgical site.
It works. But it also leaves many patients with long-term side effects — bowel problems, sexual difficulties, and chronic pelvic pain.
A new trial asked whether some patients could safely skip the radiation part.
Rectal cancer affects hundreds of thousands of people each year. For tumors that haven't yet reached the outer wall of the rectum — known as having an "uninvolved mesorectal fascia" on imaging — surgical removal usually offers a high chance of cure.
The current standard adds chemoradiation before surgery to shrink the tumor and reduce the risk of cancer returning in the pelvis. The benefit is real, but radiation has costs that don't always show up immediately. Long-term effects on the bowel, bladder, and sexual function can affect quality of life for years after treatment ends.
Researchers have been looking for ways to identify patients who don't actually need that radiation — and whose lives might be better without it.
The old way versus the new way
The standard treatment for locally advanced rectal cancer has been a structured sequence: chemoradiation first, then surgery, then more chemotherapy. The combination has a strong track record for keeping cancer from returning at the surgical site.
The new approach tested in this trial swaps out the radiation step. Instead of chemoradiation, patients receive chemotherapy alone — specifically a regimen called CAPOX (capecitabine plus oxaliplatin) — followed by surgery.
The hypothesis is straightforward. For patients whose imaging shows the cancer hasn't reached the outer rectal wall, the chemotherapy alone may be enough to control the cancer without exposing healthy tissue to radiation.
Imagine treating a stain on a delicate fabric. The aggressive approach uses a strong cleaner that removes the stain reliably but can damage the surrounding fibers. A gentler approach uses a milder treatment that may work just as well on a fresh stain — but only if you've correctly judged what kind of stain you're dealing with.
That's roughly the principle behind this trial. Radiation is the strong cleaner. Chemotherapy alone is the gentler approach. The key question is whether the diagnostic test — pre-treatment MRI — accurately identifies which patients can safely take the gentler route.
The study snapshot
The CONVERT trial enrolled 663 patients with locally advanced rectal cancer where MRI showed the outer rectal wall was uninvolved. About 300 received chemotherapy alone with CAPOX, and 289 received standard chemoradiation. The primary outcome was the rate of cancer returning at the surgical site over three years. Secondary outcomes tracked overall survival, disease-free survival, and side effects.
At three years, local recurrence was very low in both groups — 96.3% of patients on chemotherapy alone had no local cancer return, compared to 97.4% in the chemoradiation group. The difference between the two was small enough that most researchers consider the results clinically equivalent.
Disease-free survival and overall survival were also similar, with no statistically meaningful gap between the two approaches.
The clearest difference came in side effects. Patients who received chemotherapy alone had fewer long-term moderate-to-severe complications — 16% versus 26% — and lower rates of chronic proctitis, which causes pelvic pain and bowel symptoms.
The trial's strict definition of "non-inferiority" wasn't met by the narrow technical criteria. But the clinical message was clear: for the right patients, chemotherapy alone offers comparable cancer control with less long-term toxicity.
This applies only to patients whose MRI shows uninvolved outer rectal wall.
Where this fits in the bigger picture
Cancer treatment is increasingly trying to find what's called the "least intensive effective therapy." The goal isn't to do less for less's sake. It's to give each patient enough treatment to cure their cancer while preserving as much long-term quality of life as possible.
Rectal cancer is a particularly relevant area because survivorship is now measured in decades. A patient cured at 55 will live with the consequences of treatment well into their 80s. Trimming back unnecessary radiation, when safely possible, has lifelong benefits.
This trial joins others showing that careful patient selection can guide more individualized treatment decisions.
If you or a family member has been diagnosed with locally advanced rectal cancer, this study is worth bringing up with the oncology team. The key question to ask is what your pre-treatment MRI shows about the outer rectal wall.
If it shows uninvolved fascia, ask whether chemotherapy alone, without radiation, is a reasonable option. The decision involves trade-offs — local recurrence rates, side effects, your overall health, and personal preferences. The treatment team can help weigh those factors for your specific situation.
This isn't a recommendation to skip radiation in every case. It's evidence that, for a defined group of patients, doing less may be just as effective as doing more.
The trial's strict statistical definition of non-inferiority wasn't formally met, partly because both groups had such low rates of local recurrence that any small difference looked larger in relative terms. The follow-up was 48 months, which is meaningful but shorter than the decades patients live with the consequences. Selection of patients depended on accurate MRI staging, which requires experienced radiologists and high-quality imaging.
The CONVERT trial findings are likely to influence rectal cancer treatment guidelines. Expect more centers to start offering chemotherapy alone as an option for selected patients. Longer-term follow-up will clarify how the two approaches compare over 10 or more years. And ongoing trials are testing similar de-escalation strategies in other rectal cancer subgroups.
